NasdaqGS:STOK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Stoke Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: STOK has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.2%

STOK

-3.9%

US Biotechs

1.3%

US Market


1 Year Return

-0.5%

STOK

27.2%

US Biotechs

14.9%

US Market

Return vs Industry: STOK underperformed the US Biotechs industry which returned 24.5% over the past year.

Return vs Market: STOK underperformed the US Market which returned 12.5% over the past year.


Shareholder returns

STOKIndustryMarket
7 Day-2.2%-3.9%1.3%
30 Day9.4%-3.5%4.7%
90 Day8.8%7.4%17.1%
1 Year-0.5%-0.5%28.5%27.2%17.3%14.9%
3 Yearn/a26.2%22.0%38.9%29.9%
5 Yearn/a-4.2%-9.7%71.3%52.8%

Price Volatility Vs. Market

How volatile is Stoke Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Stoke Therapeutics undervalued compared to its fair value and its price relative to the market?

3.87x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate STOK's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate STOK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: STOK is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: STOK is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate STOK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: STOK is overvalued based on its PB Ratio (3.9x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Stoke Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-11.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: STOK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STOK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STOK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if STOK's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if STOK's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: STOK is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Stoke Therapeutics performed over the past 5 years?

-129.3%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: STOK is currently unprofitable.

Growing Profit Margin: STOK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if STOK's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare STOK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STOK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-22.5%).


Return on Equity

High ROE: STOK has a negative Return on Equity (-17.55%), as it is currently unprofitable.


Next Steps

Financial Health

How is Stoke Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: STOK's short term assets ($215.8M) exceed its short term liabilities ($5.5M).

Long Term Liabilities: STOK's short term assets ($215.8M) exceed its long term liabilities ($1.0M).


Debt to Equity History and Analysis

Debt Level: STOK is debt free.

Reducing Debt: STOK has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STOK has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: STOK has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 67.6% each year


Next Steps

Dividend

What is Stoke Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate STOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STOK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STOK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STOK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of STOK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Ed Kaye (71 yo)

2.83yrs

Tenure

US$668,367

Compensation

Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien ...


CEO Compensation Analysis

Compensation vs Market: Ed's total compensation ($USD668.37K) is below average for companies of similar size in the US market ($USD3.16M).

Compensation vs Earnings: Ed's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Edward Kaye
CEO & Director2.83yrsUS$668.37k0.15%
$ 1.3m
Adrian Krainer
Co-Founder6.17yrsUS$353.78k1.22%
$ 10.2m
Stephen Tulipano
Chief Financial Officer1.42yrsUS$1.26mno data
Robin Walker
Senior VP0.75yrUS$1.61mno data
Isabel Aznarez
Co-Founderno datano datano data
Huw Nash
COO & Chief Business Officer2.83yrsUS$869.86kno data
Joan Wood
Head of Human Resources0.83yrno datano data
Gene Liau
Executive VP2.58yrsno data0.041%
$ 340.1k
Barry Ticho
Chief Medical Officer2.83yrsUS$741.09k0.52%
$ 4.3m
Shamim Ruff
Senior Vice President of Regulatory Affairs & Quality1.67yrsno datano data
Nancy Wyant
VP & Head of Clinical Operations1.67yrsno datano data
Dawn Kalmar
VP & Head of Corporate Affairs1.33yrsno datano data

1.7yrs

Average Tenure

60yo

Average Age

Experienced Management: STOK's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Edward Kaye
CEO & Director2.83yrsUS$668.37k0.15%
$ 1.3m
Adrian Krainer
Co-Founder6.17yrsUS$353.78k1.22%
$ 10.2m
Seth Harrison
Independent Chairman of the Board1.17yrsUS$525.05kno data
Arthur Levin
Independent Director4.92yrsUS$282.53k0.054%
$ 452.9k
Muthiah Manoharan
Member of Scientific Advisory Board0.58yrno datano data
Julie Smith
Independent Director0.17yrno datano data
Jennifer Burstein
Independent Director1.17yrsUS$511.05kno data
Arthur Tzianabos
Independent Director1.92yrsUS$283.03kno data
Luca Cartegni
Member of Scientific Advisory Board0.58yrno datano data
Chaolin Zhang
Member of Scientific Advisory Board0.58yrno datano data
Juan Valcarcel
Member of Scientific Advisory Board0.58yrno datano data

1.2yrs

Average Tenure

60.5yo

Average Age

Experienced Board: STOK's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Stoke Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Stoke Therapeutics, Inc.
  • Ticker: STOK
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$836.745m
  • Shares outstanding: 33.22m
  • Website: https://www.stoketherapeutics.com

Number of Employees


Location

  • Stoke Therapeutics, Inc.
  • 45 Wiggins Avenue
  • Bedford
  • Massachusetts
  • 1730
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STOKNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJun 2019
0GTBST (Boerse-Stuttgart)YesCommon SharesDEEURJun 2019
0GTDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2019

Biography

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/03 00:32
End of Day Share Price2020/07/31 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.